Rxsight Q4 2024 Earnings Report
Key Takeaways
RxSight, Inc. reported a strong fourth quarter with a 41% increase in revenue compared to the same period last year. The growth was fueled by increased sales of Light Adjustable Lenses (LAL) and Light Delivery Devices (LDD). The company reaffirmed its 2025 guidance, projecting continued revenue growth and stable gross margins.
Revenue for Q4 2024 reached $40.2 million, a 41% increase compared to Q4 2023.
Sales of Light Adjustable Lenses (LAL) increased by 60%, with 29,069 units sold.
The installed base of Light Delivery Devices (LDD) expanded to 971 units, with 83 devices sold in Q4 2024.
Gross profit for Q4 2024 was $28.8 million, representing 71.6% of revenue.
Rxsight
Rxsight
Forward Guidance
The company reiterated its full-year 2025 guidance, with revenue projected to be in the range of $185.0 million to $197.0 million, gross margin in the range of 71% to 73%, and operating expenses in the range of $165.0 million to $170.0 million.
Positive Outlook
- Revenue in the range of $185.0 million to $197.0 million, representing implied growth of approximately 32% to 41% compared to 2024.
- Gross margin in the range of 71% to 73%, representing an implied increase of 30 bps to 230 bps compared to 2024.
Challenges Ahead
- Operating expenses in the range of $165.0 to $170.0 million, representing an implied increase of 22% to 25% compared to 2024.
- Operating expense guidance also includes non-cash expenses in the range of $22.0 million to $25.0 million.